Camurus AB

The FDA issued a Complete Response Letter for CAM2029 due to facility-related deficiencies found during a cGMP inspection of a third-party manufacturer. Camurus is working with the FDA and the manufacturer to resolve these issues. The CRL does not affect CAM2029's clinical efficacy or safety. Camurus remains committed to bringing CAM2029 to acromegaly patients.